Zoetis of Pfizer Inc Raises $2.2b in IPO

By Admin
Zoetis, which priced 86.1m shares at $26 according to Reuters, is now valued at a massive $13 billion. Shares in the company were expected to sell for...

 

Zoetis, which priced 86.1m shares at $26 according to Reuters, is now valued at a massive $13 billion. Shares in the company were expected to sell for between $22 and $25 each, have exceeded expectations. Zoetis sells pharmaceutical products for livestock and domestic pets.

Related news: Pfiser Zoetis Files IPO Statement

Raising over $2.2 billion in shares, Zoetis’ IPO is the largest for a US company since Facebook raised $16 billion last May. According to Reuters, the deal was between 10 and 20 times oversubscribed, meaning demand for the deal was very high.

The deal for Zoetis comes as its parent Pfizer, the world's biggest drug maker, is divesting its non-pharmaceuticals units in order to focus on its core prescription drugs business.

Last April, Pfizer sold its infant nutrition business to Nestle SA (NESN.VX) for $11.9 billion.

Source: Reuters

Share

Featured Articles

Healthcare Digital news roundup: pharma & supply chains

This week in Healthcare Digital, we looked at clinically integrated pharma supply chains, breast cancer drug trials & fighting Alzheimer’s Disease

Why clinical AI is the future of healthcare

Harish Battu from General Catalyst explores the use of AI in healthcare, the challenges of its adoption & what it means for healthcare technology

AI can help healthcare workers deliver compassionate care

Dr. Lance Owens, Chief Medical Information Officer at the University of Michigan Health-West, explains how AI technology can support healthcare workers

Digital healthcare platform Balanced supports healthy ageing

Digital Healthcare

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Medical Devices & Pharma

Cardinal Health’s clinically integrated pharma supply chain

Medical Devices & Pharma